ALN-AGT01 RVR for High Blood Pressure

This trial tests a new treatment called ALN-AGT01 RVR, a potential new drug, to evaluate its effectiveness and safety for individuals with mild to moderate high blood pressure. Participants will receive either the new treatment or a placebo (a pill with no active medicine) after taking a dose of another medication called zilebesiran. The trial seeks adults with consistently high blood pressure, specifically between 130 and 170 mmHg, who either aren't taking many blood pressure medications or have stopped most of them except certain types. The study aims to find a better way to manage high blood pressure and improve daily life for those affected. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

If you are in Part A of the trial, you can continue taking up to 2 antihypertensive medications. For Part B, you must stop all antihypertensive medications except for a calcium channel blocker or thiazide diuretic for at least 3 weeks before starting.

Research suggests that ALN-AGT01 RVR might be safe for people with high blood pressure. Earlier studies showed that ALN-AGT01, similar to ALN-AGT01 RVR, was generally well-tolerated. In these studies, patients took doses up to 800 mg without major safety concerns, and most side effects were mild and temporary.

Zilebesiran, another component of this treatment, also demonstrated a good safety record. It did not cause serious problems for patients using it for high blood pressure. The effects of zilebesiran lasted about six months, and no major issues were reported.

Unlike the standard treatments for high blood pressure, which often include ACE inhibitors or beta-blockers, ALN-AGT01 RVR works differently by targeting the angiotensinogen gene. This innovative approach uses RNA interference to reduce the production of angiotensinogen, a key protein involved in blood pressure regulation. Researchers are excited about ALN-AGT01 RVR because it offers a novel mechanism of action that could potentially lead to more precise control of blood pressure with fewer side effects. Additionally, the potential for long-lasting effects from a single dose makes it a promising candidate for simplifying blood pressure management.

Studies have shown that zilebesiran, similar to ALN-AGT01 RVR, can significantly lower blood pressure. One study found that zilebesiran reduced systolic blood pressure by an average of 15.12 mmHg, a meaningful decrease compared to a placebo, which contains no active medicine. Zilebesiran uses RNA interference to lower the production of substances that increase blood pressure. Research also shows that the effects of zilebesiran can last up to six months. This trial will compare ALN-AGT01 RVR to a placebo to evaluate its effectiveness in lowering blood pressure in people with hypertension.³⁴⁶⁷⁸